NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on ...

Fatemah grew up playing all kinds of games, initially finding a home in the very first installments of Counter-Strike and Warcraft. From there onward, it was pure grind — all day, all night.

Protagonist Therapeutics has shared a closer look at midphase data on its Johnson & Johnson-partnered oral peptide psoriasis drug candidate. The efficacy fell short of the high bar set by injectable ...

In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...

Hedge fund BVF sold 2,560,916 shares of PTGX in the fourth quarter. As a result, the quarter-end position value decreased by $170.12 million. The position was previously 6.9% of the fund's AUM as of ...

Some anime have killed their protagonists in unpredictable ways.

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...

Sales, production and finance outfit Protagonist Pictures has beefed up its marketing and sales divisions with a slew of promotions and new hires. Janina Vilsmaier, previously with Hanway before ...